Eversept Partners’s Alto Neuroscience ANRO Stock Holding History

Eversept Partners’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39M	Buy	128,286 +3,118	+2%	+$72.1K	0.18%	77
2026 Q1	$2.81M	Buy	+125,168	New	+$2.32M	0.15%	80

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Eversept Partners's ANRO Position: Q2 2026 in Review

Eversept Partners increased its Alto Neuroscience (ANRO) stake by 2.5% in Q2 2026, buying an estimated $72.1K and bringing the position to 128,286 shares worth $3.39M. The position accounts for 0.18% of the portfolio, ranked #77.

Eversept Partners first reported a position in ANRO in Q1 2026 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Eversept Partners held 128,286 shares of Alto Neuroscience worth $3.39M as of Q2 2026.
Eversept Partners bought 3,118 Alto Neuroscience shares in Q2 2026, an estimated $72.1K.
Alto Neuroscience made up 0.18% of Eversept Partners's portfolio in Q2 2026, its #77 holding.
Eversept Partners first reported a position in Alto Neuroscience in Q1 2026 and has held it in 2 quarters since.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.